title: Imatinib-mesylate for all patients with hypereosinophilic syndrome?
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Gianni
authors.initials: G
authors.lastname: Perla
authors.forename: Maria Marta
authors.initials: MM
authors.lastname: Minervini
authors.forename: Angelo Michele
authors.initials: AM
authors.lastname: Carella
authors.forename: Francesco Lo
authors.initials: FL
authors.lastname: Coco
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Catalano
mesh_terms: D001549:Benzamides; D002889:Chromosomes, Human, Pair 2; D002894:Chromosomes, Human, Pair 4; D018740:Genetic Heterogeneity; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014178:Translocation, Genetic
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate